DCGI Suspends License of PresVu Eye Drops for Presbyopia
Suspension of PresVu by DCGI
The Drug Controller General of India (DCGI) has suspended the license for PresVu, an eye drop produced by Entod Pharmaceuticals intended to diminish the necessity for reading glasses in individuals suffering from presbyopia. The suspension stems from the company's unauthorized promotions, which raised uncertainties about the product's safety.
Concerns Over Product Safety and Misuse
Sources within the government have expressed discontent over the promotional strategies utilized by Entod Pharmaceuticals, which incorrectly positioned PresVu as a non-prescription, over-the-counter (OTC) product. However, it has only been sanctioned for prescription use.
- Unauthorized Promotion: Raised safety concerns.
- Sued for suspension: Entod Pharmaceuticals plans legal actions.
- Clinical Trials: DCGI approval stemmed from trials involving 234 participants showing efficacy.
- Approved by US FDA: Similar eye drops have been marketed in the US without severe complications.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.